<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273090</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL1112</org_study_id>
    <secondary_id>COG-ADVL1112</secondary_id>
    <nct_id>NCT01273090</nct_id>
  </id_info>
  <brief_title>Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma</brief_title>
  <official_title>A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat&#xD;
      sodium in treating young patients with refractory or recurrent solid tumors or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To estimate the maximum-tolerated dose (MTD) and/or recommended phase II dose of&#xD;
           imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma.&#xD;
&#xD;
        -  To define and describe the toxicities of imetelstat sodium.&#xD;
&#xD;
        -  To characterize the pharmacokinetics of imetelstat sodium in children with refractory or&#xD;
           recurrent solid tumors or lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine, in a preliminary manner, the antitumor effects of imetelstat sodium in&#xD;
           children with refractory or recurrent solid tumors or lymphoma. (exploratory)&#xD;
&#xD;
        -  To provide preliminary assessment of the biological activity of imetelstat sodium in&#xD;
           children with recurrent or refractory malignancies by assessing telomerase activity,&#xD;
           telomere length, hTERT protein, hTERT mRNA, and hTR levels in patient peripheral blood&#xD;
           mononuclear cells (PBMNC) samples pretreatment and on treatment. (Exploratory)&#xD;
&#xD;
        -  To assess telomerase activity, hTERT expression, telomere length, hTERT protein, hTERT&#xD;
           mRNA, and hTR levels in patients' pretreatment tumor samples. (Exploratory)&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every&#xD;
      21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo blood sample collection at baseline and periodically during study for&#xD;
      pharmacokinetic and correlative studies. Tumor tissue samples from diagnosis and/or&#xD;
      subsequent tumor resections or biopsies may also be collected for correlative studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose and/or recommended phase II dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma</measure>
    <time_frame>21 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicities of imetelstat sodium</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoproliferative Disorder</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imetelstat sodium</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of refractory or recurrent solid tumors, including lymphoma&#xD;
&#xD;
               -  No CNS tumors or known CNS metastases (Part A, dose escalation)&#xD;
&#xD;
               -  CNS tumors or known CNS metastases allowed (Part B, maximum-tolerated dose or&#xD;
                  recommended phase II dose)&#xD;
&#xD;
                    -  No prior or concurrent CNS hemorrhage on a baseline MRI within the past 14&#xD;
                       days&#xD;
&#xD;
               -  All patients must have histologic verification of malignancy at original&#xD;
                  diagnosis or relapse except for:&#xD;
&#xD;
                    -  Intrinsic brain stem tumors&#xD;
&#xD;
                    -  Optic pathway gliomas&#xD;
&#xD;
                    -  Pineal tumors and elevations of CSF or serum tumor markers including&#xD;
                       alpha-fetoprotein or beta-HCG&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Disease for which there is no known curative therapy or therapy proven to prolong&#xD;
             survival with an acceptable quality of life&#xD;
&#xD;
          -  Patients with known bone marrow metastatic disease will be eligible for study provided&#xD;
             they meet the blood count criteria and they are not known to be refractory to red cell&#xD;
             or platelet transfusions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 50-100% (patients &gt; 16 years of age) OR Lansky PS&#xD;
             50-100% (patients ≤ 16 years of age)&#xD;
&#xD;
          -  ANC ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³ (transfusion-independent, defined as not receiving&#xD;
             platelet transfusion within the past 7 days prior to enrollment)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR a serum creatinine based on&#xD;
             age and/or gender as follows:&#xD;
&#xD;
               -  0.6 mg/dL (1 to &lt; 2 years of age)&#xD;
&#xD;
               -  0.8 mg/dL (2 to &lt; 6 years of age)&#xD;
&#xD;
               -  1.0 mg/dL (6 to &lt; 10 years of age)&#xD;
&#xD;
               -  1.2 mg/dL (10 to &lt; 13 years of age)&#xD;
&#xD;
               -  1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to &lt; 16 years of age)&#xD;
&#xD;
               -  1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)&#xD;
&#xD;
          -  Bilirubin (sum of conjugated and unconjugated) ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 110 U/L (ULN for ALT is 45 U/L)&#xD;
&#xD;
          -  Serum albumin ≥ 2 g/dL&#xD;
&#xD;
          -  aPTT &lt; 1.2 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use an effective contraception method&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No patients who, in the opinion of the investigator, may not be able to comply with&#xD;
             the safety monitoring requirements of the study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from acute toxic effects of all prior anti-cancer chemotherapy,&#xD;
             immunotherapy, or radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)&#xD;
&#xD;
          -  At least 14 days since prior long-acting growth factor (e.g., Neulasta) or ≥ 7 days&#xD;
             since prior short-acting growth factor&#xD;
&#xD;
          -  At least 7 days since prior biologic or anti-neoplastic agent&#xD;
&#xD;
          -  At least 6 weeks since any type of prior immunotherapy (e.g., tumor vaccines)&#xD;
&#xD;
          -  At least 3 half-lives since last dose of a monoclonal antibody&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
               -  At least 24 weeks since prior total-body irradiation, craniospinal radiotherapy,&#xD;
                  or radiation to ≥ 50% of the pelvis&#xD;
&#xD;
               -  At least 6 weeks since prior substantial bone marrow radiation&#xD;
&#xD;
          -  At least 12 weeks since prior transplantation or stem cell infusion with no evidence&#xD;
             of active graft vs host disease&#xD;
&#xD;
          -  Prior and concurrent stable or decreasing dose of corticosteroids within the past 7&#xD;
             days allowed&#xD;
&#xD;
          -  No prior allogeneic transplant&#xD;
&#xD;
          -  No other concurrent investigational drug&#xD;
&#xD;
          -  No other concurrent anticancer agents including chemotherapy, radiotherapy,&#xD;
             immunotherapy, or biologic therapy&#xD;
&#xD;
          -  No concurrent cyclosporine, tacrolimus, or other agents to prevent either&#xD;
             graft-versus-host disease post-bone marrow transplant or organ rejection&#xD;
             post-transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick A. Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley's Children Cancer Center at Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>2115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital at University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0286</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center at Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>January 29, 2014</last_update_submitted>
  <last_update_submitted_qc>January 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood anaplastic astrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligoastrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligodendroglioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood diffuse astrocytoma</keyword>
  <keyword>recurrent childhood fibrillary astrocytoma</keyword>
  <keyword>recurrent childhood gemistocytic astrocytoma</keyword>
  <keyword>recurrent childhood giant cell glioblastoma</keyword>
  <keyword>recurrent childhood glioblastoma</keyword>
  <keyword>recurrent childhood gliomatosis cerebri</keyword>
  <keyword>recurrent childhood gliosarcoma</keyword>
  <keyword>recurrent childhood oligoastrocytoma</keyword>
  <keyword>recurrent childhood oligodendroglioma</keyword>
  <keyword>recurrent childhood pilocytic astrocytoma</keyword>
  <keyword>recurrent childhood pilomyxoid astrocytoma</keyword>
  <keyword>recurrent childhood pleomorphic xanthoastrocytoma</keyword>
  <keyword>recurrent childhood protoplasmic astrocytoma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood visual pathway glioma</keyword>
  <keyword>childhood pineal parenchymal tumor</keyword>
  <keyword>recurrent childhood central nervous system embryonal tumor</keyword>
  <keyword>childhood central nervous system choriocarcinoma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood central nervous system germinoma</keyword>
  <keyword>childhood central nervous system mixed germ cell tumor</keyword>
  <keyword>childhood central nervous system teratoma</keyword>
  <keyword>childhood central nervous system yolk sac tumor</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>childhood nodular lymphocyte predominant Hodgkin lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>childhood Burkitt lymphoma</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <keyword>hepatosplenic T-cell lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>noncutaneous extranodal lymphoma</keyword>
  <keyword>peripheral T-cell lymphoma</keyword>
  <keyword>post-transplant lymphoproliferative disorder</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>small intestine lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imetelstat</mesh_term>
    <mesh_term>Motesanib diphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

